Great Tree Pharmacy Co Ltd (6469) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Great Tree Pharmacy Co Ltd stock TWD 90.94, price TWD 58.20, upside +56.3%, quality 44 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 47.88 TWD – 589.90 TWD · fair‑value band 58.24 TWD – 132.52 TWD · the 58.20 TWD price screens below the 90.94 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Great Tree Pharmacy Co in your weekly email
Every Wednesday you see whether Great Tree Pharmacy Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Great Tree Pharmacy Co., Ltd. engages in medicines, health food, maternal and infant products, and cosmetics businesses in Taiwan, Mainland China, and Malaysia. It provides drug procurement services, as well as acts as an agent for various clinics, joint clinics, and community health centers.
Show moreShow less
The company is also involved in selling food and beverages, and daily necessities; cleaning supplies; wholesale and retail of cosmetics, and other goods; cargo sorting, packaging, and warehousing; retail sale of animal medicines and ornamental animals; fish and pet food retail; medical equipment and pet-related products; wholesale of precision instruments; development and retail business; biotechnology; investment business, and specific specialized zones businesses.
In addition, it provides technical services; management consultants, residential and building properties; development, leasing, rental, and sales of real estate; property leasing; industrial plant development; biotechnology research and development; and other wholesale and retail business.
The company was formerly known as Tianjin Pharmaceutical Co., Ltd. and changed its products to Great Tree Pharmacy Co., Ltd. The company was incorporated in 2001 and is based in Taoyuan City, Taiwan.
Stock analysis
Great Tree Pharmacy Co Ltd (6469) currently trades at 58.20 TWD, while our model-based Fair Value estimate is 90.94 TWD, implying the stock looks roughly 36% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 131.95 TWD per share, and 19 of the 26 models we run sit above the 58.20 TWD price.
Bear case: the Asset-Based group reads lowest at 16.14 TWD, and 7 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 58.24 TWD (bear) to 132.52 TWD (bull), the price of 58.20 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Great Tree Pharmacy Co Ltd reported revenue of 18.9B TWD in FY2025 versus 11.3B TWD in FY2021, a compound +13.8%/yr. Reported net income was 600M TWD in FY2025, compounding +10.2%/yr from FY2021.
Key figures
Market cap 9.3B TWD (≈ $282M) Micro · P/E ratio 18.5 · P/S ratio 0.48 · EPS (TTM) 3.15 TWD · Dividend yield 5.1% · Net margin 2.7% · Return on equity 13.5% · Return on assets (EBIT) 7.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 56%, 6469 screens cheaper than that median.
Fair Value models
Bear58.24 TWDFair Value 90.94 TWDBull132.52 TWD
Price 58.20 TWD · Upside +56.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1466 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF72.82 TWD101.74 TWD186.97 TWD78
Growth DCF68.52 TWD106.99 TWD176.38 TWD77
Residual Income22.93 TWD26.92 TWD34.42 TWD76
All 26 models by family
DCF Models
FCF DCF72.82 TWD101.74 TWD186.97 TWD78
Owner Earnings66.42 TWD128.46 TWD239.71 TWD73
5Y Revenue Exit56.09 TWD88.99 TWD157.04 TWD70
5Y EBITDA Exit91.97 TWD161.78 TWD297.98 TWD72
5Y P/E Exit67.50 TWD136.82 TWD229.71 TWD68
10Y Revenue Exit60.52 TWD113.99 TWD146.47 TWD67
10Y EBITDA Exit84.97 TWD181.39 TWD354.78 TWD64
10Y P/E Exit69.25 TWD135.43 TWD244.83 TWD61
Earnings-Based
Graham-Dodd25.67 TWD179.02 TWD251.23 TWD63
Lynch FV65.14 TWD93.06 TWD120.97 TWD61
PEG = 1.065.14 TWD93.06 TWD120.97 TWD57
EPV29.51 TWD32.61 TWD35.16 TWD74
Dividend Discount
Gordon GGM20.13 TWD34.82 TWD46.35 TWD68
DDM Multi-Stage20.13 TWD32.49 TWD37.35 TWD67
Multiples
P/E Multiple59.46 TWD79.28 TWD99.10 TWD63
P/S Multiple48.13 TWD64.18 TWD80.22 TWD58
P/B Multiple99.40 TWD132.53 TWD165.66 TWD55
EV/EBIT50.96 TWD69.38 TWD87.80 TWD66
EV/EBITDA92.02 TWD124.13 TWD156.24 TWD67
EV/Revenue35.14 TWD52.04 TWD68.95 TWD53
Asset-Based
NCAV (Graham)12.05 TWD16.14 TWD24.10 TWD54
Growth DCF
Growth DCF68.52 TWD106.99 TWD176.38 TWD77
Rev-Margin DCF56.09 TWD101.05 TWD182.18 TWD70
Economic Profit
Residual Income22.93 TWD26.92 TWD34.42 TWD76
ROIC Compounder32.95 TWD42.82 TWD49.18 TWD72
Growth Earnings
Growth-Adj P/E83.95 TWD119.93 TWD155.90 TWD67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +24.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+22.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.7%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.7% vs 16.4%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 4%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +2.2% a year for the price.
Compare Great Tree Pharmacy Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside+57.3% · Top 25%
Profitability
Return on equity (12 months)13.5% · Top 25%
Return on assets4.4% · Above median
Net margin (12 months)2.7% · Above median
Operating margin (12 months)2.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−1.0% · Below median
Dividend yield (12 months)5.1% · Top 25%
Balance sheet
Debt / equity0.24× · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (12 months)18.5× · Cheaper than median
P/B2.35× · Pricier than median
P/S (12 months)0.48× · Cheaper than median
Price / free cash flow (fiscal year)11.7× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Great Tree Pharmacy Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6469
Frequently asked questions
Is Great Tree Pharmacy Co Ltd (6469) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 90.94 TWD versus a price of 58.20 TWD, about +56% upside (undervalued).
What is the fair value of 6469?
Our model-based fair value for Great Tree Pharmacy Co Ltd is 90.94 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 58.20 TWD.
What is the quality score of 6469?
Great Tree Pharmacy Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Great Tree Pharmacy Co Ltd (6469)?
Our model-based price target is the fair value of 90.94 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 58.24 TWD, optimistic scenario 132.52 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Great Tree Pharmacy Co Ltd stock forecast for 2026?
Our models put fair value at 90.94 TWD, about +56% upside versus a price of 58.20 TWD (undervalued). Cautious scenario 58.24 TWD, optimistic scenario 132.52 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Great Tree Pharmacy Co Ltd (6469)?
Great Tree Pharmacy Co Ltd reported trailing-twelve-month revenue of about 19.0B TWD (latest available figure, as of Nov 8, 2026).
Does Great Tree Pharmacy Co Ltd pay a dividend?
Great Tree Pharmacy Co Ltd currently shows a dividend yield of 5.12% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Great Tree Pharmacy Co Ltd (6469) and when is the ex-dividend date?
Great Tree Pharmacy Co Ltd pays a dividend of 2.98 TWD per share a year, a dividend yield of 5.1%. The last ex-dividend date was Aug 4, 2026. A dividend has been paid every year since at least 2015. The payout ratio is 103% of earnings (on adjusted earnings, reported 94.6%). Free cash flow covers the dividend 1.66 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Great Tree Pharmacy Co Ltd (6469)?
For today's price to be fair in a discounted-cash-flow model, Great Tree Pharmacy Co Ltd would have to grow free cash flow by +3.8 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 6469 use?
Our models discount Great Tree Pharmacy Co Ltd at 11.8 %: a base by market capitalisation (small), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Great Tree Pharmacy Co Ltd that is +3.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Great Tree Pharmacy Co Ltd (6469) delivered so far?
Over the past 5 years revenue at Great Tree Pharmacy Co Ltd grew +16.9 % a year. The price currently implies free-cash-flow growth of +3.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Great Tree Pharmacy Co Ltd (6469) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Great Tree Pharmacy Co Ltd (+3.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Great Tree Pharmacy Co Ltd (6469)?
The free-cash-flow yield on the price is 9.04 %: that much free cash flow Great Tree Pharmacy Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Great Tree Pharmacy Co Ltd (6469)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Great Tree Pharmacy Co Ltd it is 90.94 TWD per share (as of Nov 8, 2026), against a price of 58.20 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Great Tree Pharmacy Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6469 trades below its calculated fair value: price 58.20 TWD, fair value 90.94 TWD, a gap of about +56% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6469?
No. The price is what the market pays today (58.20 TWD); the fair value is what the company's own numbers justify (90.94 TWD). For Great Tree Pharmacy Co Ltd the two are 32.74 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Great Tree Pharmacy Co Ltd worth?
The market values Great Tree Pharmacy Co Ltd at about 9.3B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 58.20 TWD; our models calculate a fair value of 90.94 TWD per share.
What do the bullish and bearish scenarios say about 6469?
Our models span a range for Great Tree Pharmacy Co Ltd: cautious scenario 58.24 TWD, base 90.94 TWD, optimistic 132.52 TWD per share (as of Nov 8, 2026, price 58.20 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6469?
Great Tree Pharmacy Co Ltd trades at a price-to-earnings ratio of 18.5 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 90.94 TWD is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 15.9 (reported for FY2025: 14.5). Other multiples: P/B 2.4, P/S 0.5, EV/EBITDA 10.7.
How solid is the balance sheet of Great Tree Pharmacy Co Ltd (6469)?
Balance-sheet figures for Great Tree Pharmacy Co Ltd (as of Nov 8, 2026): return on equity 13.5%, debt of 0.24 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6469 from its 52-week high?
Great Tree Pharmacy Co Ltd trades at 58.20 TWD, about 43% below its 52-week high of 101.42 TWD and 1% above the low of 57.80 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 90.94 TWD is for.
Which stocks are comparable to Great Tree Pharmacy Co Ltd?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Great Tree Pharmacy Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price 58.20 TWD, calculated fair value 90.94 TWD (+56%), Quality Score 44/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6469 calculated?
We run Great Tree Pharmacy Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 90.94 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Great Tree Pharmacy Co Ltd currently trades 36% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Great Tree Pharmacy Co Ltd (6469)?
The closing price on Nov 9, 2026 was 58.20 TWD. Our model-based fair value is 90.94 TWD, about +56% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Great Tree Pharmacy Co Ltd right now?
The large discount to fair value meets weak quality (44/100). That raises the risk this is a value trap rather than a bargain. A fairly wide model range (58.24 TWD to 132.52 TWD) leaves room in how you read the outcome.
Where does the earnings growth of Great Tree Pharmacy Co Ltd (6469) come from?
Earnings per share at Great Tree Pharmacy Co Ltd grew +21.7 % a year from 2012 to 2023. Broken into its drivers: revenue per share +24.9 %, EBIT margin −1.2 %, tax rate −0.3 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Great Tree Pharmacy Co Ltd
How large is the market capitalisation of Great Tree Pharmacy Co Ltd (6469)?
The market capitalisation of Great Tree Pharmacy Co Ltd is 9.3B TWD (≈ $282M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Great Tree Pharmacy Co Ltd (6469)?
The price-to-sales ratio of Great Tree Pharmacy Co Ltd is 0.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Great Tree Pharmacy Co Ltd (6469)?
Earnings per share at Great Tree Pharmacy Co Ltd are 3.15 TWD (price ÷ EPS = P/E 18.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Great Tree Pharmacy Co Ltd (6469)?
The dividend yield of Great Tree Pharmacy Co Ltd is 5.1% (payout 103%, on adjusted earnings, reported 94.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Great Tree Pharmacy Co Ltd (6469)?
The net margin of Great Tree Pharmacy Co Ltd is 2.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Great Tree Pharmacy Co Ltd (6469)?
The return on equity (ROE) of Great Tree Pharmacy Co Ltd is 13.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Great Tree Pharmacy Co Ltd (6469)?
On an EBIT basis the return on assets of Great Tree Pharmacy Co Ltd is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Great Tree Pharmacy Co Ltd (6469)?
The operating margin of Great Tree Pharmacy Co Ltd is 2.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Great Tree Pharmacy Co Ltd (6469)?
Revenue at Great Tree Pharmacy Co Ltd is growing −1.0% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Great Tree Pharmacy Co Ltd (6469)?
Earnings per share at Great Tree Pharmacy Co Ltd are growing −31.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Great Tree Pharmacy Co Ltd (6469) carry?
The net debt of Great Tree Pharmacy Co Ltd is 684M TWD (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Great Tree Pharmacy Co Ltd in the live analysis
One click puts Great Tree Pharmacy Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026